Tendril STS Leads; Ultipace Leads
ABBOTT MEDICAL · Decision date Dec 9, 2025
What did the FDA decide?
FDA records P960013/S132 as a supplement to PMA P960013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 9, 2025.
FDA approval order statement
to move a supplier's manufacturing site for implantable lead subcomponents
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 9, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P960013/S132
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NVN
- Decision code
- OK30
- Decision date
- Dec 9, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug eluting permanent right ventricular (RV) or right atrial (RA) pacemaker electrodes.
- Applicant
- Abbott Medical
- Product code
- NVN
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P960013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P960013 · Original PMA
TENDRIL DX MODEL 1388T & 1388K ENDOCARDIAL PACING LEADS
P960013/S132 received
Application receipt date recorded by FDA.
P960013/S131 · Related supplement
OptiSense Pacing Leads
P960013/S132 · FDA decision
30-Day Notice
P960013/S129 · Related supplement
Tendril STS; OptiSense; UltiPace
P960013/S133 · Related supplement
UltiPace Low Voltage LPA1231, Tendril Low Voltage 2088TC, OptiSense Low Voltage 1999, Isoflex Low Voltage 1944/1948, Ten
P960013/S134 · Related supplement
Tendril STS Leads; Ultipace Leads; Optisense Leads
P960013/S135 · Related supplement
Motorized Outer Tubing Cutter for UltiPace Leads
Timeline entries are records held by MedtechLedger for P960013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P960013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Jun 20, 1997 | FDA | |
OptiSense Pacing LeadsP960013/S131 | ABBOTT MEDICAL | PMA supplement | Nov 20, 2025 | FDA |
Tendril STS; OptiSense; UltiPaceP960013/S129 | ABBOTT MEDICAL | PMA supplement | Feb 19, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Jun 11, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Jun 26, 2026 | FDA | |
Motorized Outer Tubing Cutter for UltiPace LeadsP960013/S135 | ABBOTT MEDICAL | PMA supplement | Oct 9, 2026 | FDA |
Explore the linked device profile
Other records with product code NVN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MEDTRONIC SELECTSECURE LEAD MODEL 3830P030036/S162 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 16, 2026 | FDA |
SelectSecure Lead 3830P030036/S161 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Aug 5, 2026 | FDA |
IsoFlex LeadsP960030/S085 | ABBOTT MEDICAL | PMA supplement | Jun 26, 2026 | FDA |
SelectSecure Lead (3830)P030036/S160 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Jun 24, 2026 | FDA |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Jun 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 15900 Valley View Ct., Sylmar, CA, 91335
Sources and methodology
- Original FDA record: P960013/S132
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






